The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ILLUCCIX (Telix Pharmaceuticals (ANZ) Pty Ltd)
Product name
ILLUCCIX
Date registered
Evaluation commenced
Decision date
Approval time
120 (255 working days)
Active ingredients
Glu-urea-Lys(ahx)-hbed-CC
Registration type
NCE/NBE
Indication
ILLUCCIX (powder and dilutent for injection), after radiolabelling with Ga-68, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging combined with computerised tomography (CT) in patients with prostate cancer:
- who are at risk of metastasis and who are suitable for initial definitive therapy.
- who have suspected recurrence based on elevated serum prostate specific antigen (PSA) level.